Gilead-GS-US-546-5920: A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Myeloid Malignancies

Protocol No
GILEAD-GS-US-546-5920
Principal Investigator
Guru Subramanian Guru Murthy
Phase
II
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of magrolimab in combination with other therapies for patients who have been newly diagnosed with AML and are unfit for intensive chemotherapy, or have relapsed refractory AML, or have Minimal Residual Disease (MRD)-positive AML disease after reaching complete remission (no more signs of leukemia after treatment).
Description
Magrolimab Combinations in Patients with Myeloid Malignancies
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL